Theoretically, neutralising monoclonal antibodies could be used to target antigens involved in cancer development, and a recent phase I/II clinical trial has taken this approach with chimeric mouse/dog anti-podoplanin antibody [141]. The gene discussed is PDPN; the disease is cancer.